Amedeo Smart

Free Medical Literature Service

 

Amedeo

Asthma
  Free Subscription

Articles published in
Eur Respir J
    August 2025
  1. LEE B, Wong E, Tan T, Rupani H, et al
    Pregnancy, asthma and exacerbations: a population-based cohort.
    Eur Respir J. 2025 Aug 28:2501327. doi: 10.1183/13993003.01327-2025.
    >> Share

  2. WILKINSON TMA, Akuthota P
    CompEx Asthma: is it time for a change in clinical trials?
    Eur Respir J. 2025 Aug 21:2500470. doi: 10.1183/13993003.00470-2025.
    >> Share

    July 2025
  3. LIU KY, Sie JJ, Gao Y, Lo YL, et al
    Functional sequence variants of intergenic long non-coding RNA on Chromosome 17q21 are associated with asthma.
    Eur Respir J. 2025 Jul 3:2500847. doi: 10.1183/13993003.00847-2025.
    >> Share

  4. MENON L, Blakey J, Ramakrishnan S
    Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500685.
    >> Share

  5. CELIS-PRECIADO C, Lemaire-Paquette S, Lachapelle P, Couillard S, et al
    Reply to: Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500949.
    >> Share

    June 2025
  6. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
    Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
    Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
    >> Share

    May 2025
  7. GIRAULT A, Le A, Gonsard A, Abou Taam R, et al
    ChatGPT and Other Large Language Models for Parents' Questions About Childhood Asthma: A Comparative Study.
    Eur Respir J. 2025 May 15:2500254. doi: 10.1183/13993003.00254-2025.
    >> Share

  8. BUSSE WW, O'Byrne PM
    Are systemic corticosteroids needed for all asthma exacerbations?
    Eur Respir J. 2025;65:2500370.
    >> Share

    April 2025
  9. YANG F, Bossios A
    Who really responds to asthma biologics? The clue lies in the journey before treatment.
    Eur Respir J. 2025;65:2500044.
    >> Share


  10. "Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways." B. Stikker, L. Trap, B. Sedaghati-Khayat, et al. Eur Respir J 2024; 64: 2302059.
    Eur Respir J. 2025;65:2352059.
    >> Share

  11. KOURID MI, Couillard S
    Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
    Eur Respir J. 2025;65:2500153.
    >> Share

  12. HAMADA Y, Thomas D, Gibson PG
    Reply to: Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500516.
    >> Share


  13. "Advancing patient-centred care in measuring response to biologics in severe asthma." Vanesa Bellou. Eur Respir J 2025; 65: 2402113.
    Eur Respir J. 2025;65:2452113.
    >> Share

  14. TAKEFUJI Y
    Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500423.
    >> Share

    March 2025
  15. BELLOU V
    Advancing patient-centred care in measuring response to biologics in severe asthma.
    Eur Respir J. 2025;65:2402113.
    >> Share

    February 2025
  16. BOURDIN A, Nogue E, Matzner-Lober E, Malafaye N, et al
    What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study.
    Eur Respir J. 2025 Feb 27:2402264. doi: 10.1183/13993003.02264-2024.
    >> Share

  17. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
    Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
    Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
    >> Share

  18. MAILHOT-LAROUCHE S, Busby J, Couillard S
    Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402057.
    >> Share

  19. MARTIN N, Wechsler ME, Brightling CE
    Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402434.
    >> Share

    January 2025
  20. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    >> Share

  21. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    >> Share

  22. NOLASCO S, Mukherjee M, Nair P
    Trajectories of responses to mepolizumab in severe asthma.
    Eur Respir J. 2025;65:2402023.
    >> Share


  23. ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma.
    Eur Respir J. 2025;65:25E6501.
    >> Share

    December 2024
  24. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    >> Share

  25. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    >> Share

    November 2024
  26. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    >> Share

  27. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    >> Share

  28. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    >> Share

    October 2024
  29. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    >> Share

  30. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    >> Share

  31. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    >> Share

    September 2024
  32. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    >> Share

  33. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    >> Share

  34. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    >> Share

  35. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    >> Share

  36. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    >> Share

  37. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    >> Share

    August 2024
  38. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    >> Share

  39. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    >> Share

  40. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    >> Share

  41. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    >> Share

  42. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    >> Share

  43. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    >> Share

    July 2024
  44. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    >> Share

  45. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    >> Share

  46. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    >> Share

  47. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    >> Share

    June 2024
  48. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    >> Share

  49. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    >> Share

  50. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    >> Share

  51. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    >> Share

  52. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    >> Share

  53. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    >> Share

  54. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    >> Share

    May 2024
  55. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    >> Share

  56. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    >> Share

  57. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    >> Share

  58. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    >> Share

  59. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    >> Share

  60. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    >> Share

    April 2024
  61. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    >> Share

  62. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    >> Share

  63. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    >> Share

  64. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    >> Share

  65. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    >> Share

  66. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    >> Share

  67. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    >> Share

  68. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    >> Share


  69. ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    >> Share

    March 2024
  70. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    >> Share

  71. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    >> Share

  72. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    >> Share


  73. "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
    Eur Respir J. 2024;63:2351788.
    >> Share


  74. "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
    Eur Respir J. 2024;63:1852422.
    >> Share

    February 2024
  75. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    >> Share

    August 2023

  76. ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016